KAT6B/KANSL1 gene fusion probe reagent

Reference: [1]DundrP, DvořákJ, KrausováM, etal. Uterine sarcoma with KAT6B/A::KANSL1 fusion: a molecular and clinicopathological study on 9 cases [J]. Virchows Archiv, 2024:1-12. [2]Agaimy A, Clarke B A, Kolin D L, etal. Recurrent KAT6B/A::KANSL1 fusions characterize a potentially aggressive uterine sarcoma morphologically overlapping with low-grade endometrial stromal sarcoma. Am J Surg Pathol. 2022;46(9):1298–1308. [3]Trecourt A, Azmani R, HosteinI, et al. The KAT6B::KANSL1 fusion defines a new uterine sarcoma with hybrid endometrial stromal tumor and smooth muscle tumor features. Mod Pathol. 2023:100243.